Merkle Capital launches regulated INJ fund in Asia
Merkle Capital, a Thailand-based digital asset manager, launched the M-INJ fund on June 4, 2026—marking the first regulated investment vehicle in Asia built exclusively around Injective’s native token, INJ. The fund is supervised by Thailand’s Securities and Exchange Commission (SEC), aiming to give both retail and institutional investors compliant INJ exposure without relying on unregulated exchanges.
Merkle Capital said it previously secured a Digital Asset Fund Management license from the Thai SEC in January 2022 and built custody and compliance infrastructure for earlier products, including Bitcoin-focused strategies and a managed Ethereum strategy (M-ETHE). M-INJ is a single-asset structure: the fund holds only INJ, with no diversified basket to reduce volatility.
Traders should note the broader regulatory backdrop for INJ. In the US, INJ futures are already trading on Bitnomial, a CFTC-regulated venue. By mid-2026, multiple institutions—including Canary Capital—have filed applications for spot INJ exchange-traded funds (ETFs).
For market participants, M-INJ mainly improves access and reduces operational friction for institutions, potentially supporting demand and liquidity for INJ. The key downside is concentration risk: as a single-asset INJ fund, price moves flow directly into the fund’s performance, while regulation does not hedge market risk.
Bullish
This is likely bullish for INJ in the short-to-medium term because the launch of a Thailand SEC-supervised, single-asset INJ fund improves institutional and retail access. In crypto history, similar “regulated wrapper” events (e.g., fund launches or jurisdictional approvals for major tokens) often catalyze incremental demand by lowering custody, auditing, and counterparty friction—two practical barriers that typically suppress institutional participation.
However, the fund’s single-asset concentration means the upside is paired with direct downside: if INJ drops, the fund falls proportionally. That can limit defensive positioning, but it doesn’t negate the access effect.
Longer term, the US regulatory tailwinds cited—CFTC-regulated INJ futures trading and ongoing INJ ETF filings (e.g., Canary Capital)—can reinforce positive expectations. If ETF approvals progress, market participants may re-rate INJ based on improved liquidity and broader distribution. Conversely, any delays or setbacks in US ETF decisions could cool momentum, making the impact more path-dependent than a typical diversified product.
Net: access + regulatory legitimacy for INJ is the dominant signal, outweighing the concentration risk, hence bullish.